Merck & Co., Inc. (NYSE:MRK) Shares Bought by Zhang Financial LLC

Zhang Financial LLC grew its position in Merck & Co., Inc. (NYSE:MRKGet Rating) by 15.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,012 shares of the company’s stock after buying an additional 2,058 shares during the quarter. Zhang Financial LLC’s holdings in Merck & Co., Inc. were worth $1,369,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Merck & Co., Inc. by 2.3% in the first quarter. Vanguard Group Inc. now owns 216,096,057 shares of the company’s stock valued at $17,730,682,000 after purchasing an additional 4,893,526 shares during the period. BlackRock Inc. boosted its stake in Merck & Co., Inc. by 3.0% during the first quarter. BlackRock Inc. now owns 204,122,526 shares of the company’s stock worth $16,748,252,000 after buying an additional 5,898,263 shares in the last quarter. State Street Corp boosted its stake in Merck & Co., Inc. by 2.7% during the fourth quarter. State Street Corp now owns 118,668,673 shares of the company’s stock worth $9,174,491,000 after buying an additional 3,132,078 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Merck & Co., Inc. by 5.9% in the 1st quarter. Bank of New York Mellon Corp now owns 32,792,528 shares of the company’s stock valued at $2,690,627,000 after purchasing an additional 1,822,084 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Merck & Co., Inc. by 3.7% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 30,079,662 shares of the company’s stock valued at $2,468,037,000 after purchasing an additional 1,077,042 shares in the last quarter. 73.33% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have commented on MRK. UBS Group increased their price objective on shares of Merck & Co., Inc. from $76.00 to $98.00 and gave the stock a “neutral” rating in a report on Monday, July 18th. Cowen increased their price objective on shares of Merck & Co., Inc. from $95.00 to $102.00 and gave the stock a “market perform” rating in a report on Monday, June 27th. Berenberg Bank raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and increased their price objective for the stock from $95.00 to $100.00 in a report on Wednesday, September 14th. Daiwa Capital Markets upgraded shares of Merck & Co., Inc. from a “neutral” rating to a “buy” rating and upped their target price for the company from $89.00 to $102.00 in a research report on Wednesday, July 6th. Finally, Atlantic Securities upped their target price on shares of Merck & Co., Inc. from $105.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, July 13th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and a consensus target price of $98.28.

Merck & Co., Inc. Stock Performance

Merck & Co., Inc. stock opened at $87.51 on Friday. The stock has a market cap of $221.69 billion, a PE ratio of 13.40, a P/E/G ratio of 1.14 and a beta of 0.33. The company has a quick ratio of 1.15, a current ratio of 1.39 and a debt-to-equity ratio of 0.66. The business’s 50-day moving average price is $88.83 and its two-hundred day moving average price is $87.81. Merck & Co., Inc. has a 12-month low of $71.50 and a 12-month high of $95.72.

Merck & Co., Inc. (NYSE:MRKGet Rating) last released its quarterly earnings results on Thursday, July 28th. The company reported $1.87 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.20. The company had revenue of $14.59 billion for the quarter, compared to analysts’ expectations of $13.85 billion. Merck & Co., Inc. had a return on equity of 48.45% and a net margin of 29.00%. The business’s quarterly revenue was up 28.0% compared to the same quarter last year. During the same period in the previous year, the business posted $1.31 earnings per share. As a group, analysts expect that Merck & Co., Inc. will post 7.33 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 7th. Investors of record on Thursday, September 15th will be issued a $0.69 dividend. This represents a $2.76 annualized dividend and a yield of 3.15%. The ex-dividend date of this dividend is Wednesday, September 14th. Merck & Co., Inc.’s payout ratio is presently 42.27%.

Merck & Co., Inc. Profile

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

See Also

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.